Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors.
- DOI
- 10.1080/14737140.2026.2733826
- Published
- 2026 Sep 17
- Container
- Expert review of anticancer therapy
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14737140.2026.2733826,
title = {Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors.},
author = {Karatlı S and Yazılıtaş D and Altınbaş M},
year = {2026},
journal = {Expert review of anticancer therapy},
doi = {10.1080/14737140.2026.2733826},
url = {https://doi.org/10.1080/14737140.2026.2733826}
}RIS
TY - JOUR TI - Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors. AU - Karatlı S AU - Yazılıtaş D AU - Altınbaş M PY - 2026 JO - Expert review of anticancer therapy DO - 10.1080/14737140.2026.2733826 UR - https://doi.org/10.1080/14737140.2026.2733826 ER -
APA
S, K., D, Y., & M, A. (2026). Real-world outcomes of ribociclib treatment in HR-positive/HER2-negative metastatic breast cancer: efficacy, safety, and prognostic factors.. Expert review of anticancer therapy. https://doi.org/10.1080/14737140.2026.2733826
Source records
- pubmed · retrieved 2026-09-26T20:23:18.557Z